文献速递神经肿瘤

垂体腺瘤周围神经解剖结构的剂量与立体定向放射外科对神经内分泌功能的影响:一项国际多中心研究

Dose to neuroanatomical structures surrounding pituitary adenomas and the effect of stereotactic radiosurgery on neuroendocrine function: an international multicenter study.
PubMed 文献 · J Neurosurg · 2021-09-24

该国际多中心回顾性研究纳入1997至2019年间16家中心接受单次立体定向放射外科(SRS)治疗的521例垂体腺瘤患者,对14个下丘脑-垂体轴预定神经解剖结构进行点剂量测量。中位随访60.1个月,肿瘤控制率达93.9%,22.5%患者出现新发垂体功能减退;垂体柄中位剂量阈值10.7 Gy与内分泌功能恶化独立相关(OR 1.77,95%CI 1.17-2.68,p=0.006)。

要点

  • 垂体柄单次剂量阈值10.7 Gy显著增加SRS后垂体功能减退风险(OR 1.77,95%CI 1.17-2.68,p=0.006)。
  • 正常垂体腺接受更高剂量、非功能性腺瘤、较年轻年龄及较高边缘剂量均为新发或加重垂体功能减退的独立预测因素。
  • 下丘脑剂量及垂体柄与腺体剂量比值并非显著预测因素,SRS总体肿瘤控制率达93.9%。

核心结论

  • SRS治疗垂体腺瘤可获得高肿瘤控制率,新发或加重内分泌病变风险可接受。
  • 垂体柄剂量(阈值10.7 Gy)和正常垂体腺剂量显著增加SRS后垂体功能减退风险。
  • 对SRS前神经内分泌功能保留的患者,限制垂体柄和腺体剂量同时给予肿瘤最佳剂量似乎是审慎的。

研究设计与样本

  • 国际放射外科研究基金会(IRRF)多中心回顾性研究,纳入1997至2019年16家机构接受单次SRS的垂体腺瘤患者。
  • 对下丘脑、垂体柄和正常垂体腺沿线的14个预定神经解剖结构进行点剂量测量。
  • 研究队列共521例垂体腺瘤,中位随访60.1个月,中位治疗体积3.2 cm3。

主要发现

  • 肿瘤控制率达93.9%,22.5%患者出现新发垂体功能丧失。
  • 下丘脑、垂体柄和正常垂体腺的中位最大放射外科剂量分别为1.4、7.2和11.3 Gy。
  • 非功能性腺瘤状态、较年轻年龄、较高边缘剂量以及较高垂体柄和正常垂体腺剂量是新发或加重垂体功能减退的独立预测因素。
  • 下丘脑剂量及垂体柄与腺体剂量比值均非显著预测因素。
  • 垂体柄中位剂量对新发内分泌病变的阈值为单次10.7 Gy(OR 1.77,95%CI 1.17-2.68,p=0.006)。

关键数值与推荐

  • 垂体柄中位剂量阈值10.7 Gy对应新发内分泌病变风险增加(OR 1.77,95%CI 1.17-2.68,p=0.006)。

临床怎么用

  • 对SRS前神经内分泌功能保留的垂体腺瘤患者,应限制垂体柄和正常垂体腺剂量,同时给予肿瘤最佳剂量。
  • 非功能性腺瘤、较年轻患者及接受较高边缘剂量者需关注垂体功能减退风险。

局限性

  • 本研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stereotactic radiosurgery (SRS) provides a safe and effective therapeutic modality for patients with pituitary adenomas. The mechanism of delayed endocrine deficits based on targeted radiation to the hypothalamic-pituitary axis remains unclear. Radiation to normal neuroendocrine structures likely plays a role in delayed hypopituitarism after SRS. In this multicenter study by the International Radiosurgery Research Foundation (IRRF), the authors aimed to evaluate radiation tolerance of structures surrounding pituitary adenomas and identify predictors of delayed hypopituitarism after SRS for these tumors. METHODS: This is a retrospective review of patients with pituitary adenomas who underwent single-fraction SRS from 1997 to 2019 at 16 institutions within the IRRF. Dosimetric point measurements of 14 predefined neuroanatomical structures along the hypothalamus, pituitary stalk, and normal pituitary gland were made. Statistical analyses were performed to determine the impact of doses to critical structures on clinical, radiographic, and endocrine outcomes. RESULTS: The study cohort comprised 521 pituitary adenomas treated with SRS. Tumor control was achieved in 93.9% of patients over a median follow-up period of 60.1 months, and 22.5% of patients developed new loss of pituitary function with a median treatment volume of 3.2 cm3. Median maximal radiosurgical doses to the hypothalamus, pituitary stalk, and normal pituitary gland were 1.4, 7.2, and 11.3 Gy, respectively. Nonfunctioning adenoma status, younger age, higher margin dose, and higher doses to the pituitary stalk and normal pituitary gland were independent predictors of new or worsening hypopituitarism. Neither the dose to the hypothalamus nor the ratio between doses to the pituitary stalk and gland were significant predictors. The threshold of the median dose to the pituitary stalk for new endocrinopathy was 10.7 Gy in a single fraction (OR 1.77, 95% CI 1.17-2.68, p = 0.006). CONCLUSIONS: SRS for the treatment of pituitary adenomas affords a high tumor control rate with an acceptable risk of new or worsening endocrinopathy. This evaluation of point dosimetry to adjacent neuroanatomical structures revealed that doses to the pituitary stalk, with a threshold of 10.7 Gy, and doses to the normal gland significantly increased the risk of post-SRS hypopituitarism. In patients with preserved pre-SRS neuroendocrine function, limiting the dose to the pituitary stalk and gland while still delivering an optimal dose to the tumor appears prudent.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Pomeraniec IJ, Xu Z, Lee CC, et al. Dose to neuroanatomical structures surrounding pituitary adenomas and the effect of stereotactic radiosurgery on neuroendocrine function: an international multicenter study. J Neurosurg. 2021. PMID: 34560630. doi:10.3171/2021.3.JNS203812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。